Search

Your search keyword '"Mirabel, X."' showing total 605 results
Start Over Author "Mirabel, X."
605 results on '"Mirabel, X."'

152. STEREOTACTIC RADIOTHERAPY AND ELDERLY PATIENTS

Author

Dewas, S., primary, Vautravers-Dewas, C., additional, Servent, V., additional, Mirabel, X., additional, Prevost, B., additional, Coche, B., additional, Castelain, B., additional, Nickers, P., additional, Bibault, J.E., additional, and Lartigau, E., additional

Published
2011
Full Text
View/download PDF

154. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer

Author

Conroy, T, primary, Yataghène, Y, additional, Etienne, P L, additional, Michel, P, additional, Senellart, H, additional, Raoul, J L, additional, Mineur, L, additional, Rives, M, additional, Mirabel, X, additional, Lamezec, B, additional, Rio, E, additional, Le Prisé, E, additional, Peiffert, D, additional, and Adenis, A, additional

Published
2010
Full Text
View/download PDF

156. Clinicopathological Study of 13 Cases of Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa

Author

Lavogiez, C., primary, Delaporte, E., additional, Darras-Vercambre, S., additional, Martin De Lassalle, E., additional, Castillo, C., additional, Mirabel, X., additional, Laurent, F., additional, Patenotre, P., additional, Gheit, T., additional, Talmant, J.C., additional, Beylot-Barry, M., additional, Martinot, V., additional, Piette, F., additional, Aubin, F., additional, and Mortier, L., additional

Published
2009
Full Text
View/download PDF

166. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial

Author

Conroy, T., primary, Ducreux, M., additional, Lemanski, C., additional, Francois, E., additional, Giovannini, M., additional, Cvitkovic, F., additional, Mirabel, X., additional, Bouché, O., additional, Montoto-Grillot, C., additional, and Peiffert, D., additional

Published
2009
Full Text
View/download PDF

168. P.182 Impact pronostique des variables thérapeutiques sur une cohorte de patients avec cancers de l’œsophage cervical et de l’œsophage sus-carénaire traités par radiochimiothérapie (RCT) exclusive

Author

Mirabel, X., primary, Chaouache, K., additional, Gras, L., additional, Penel, N., additional, Dominguez, S., additional, Kouto, H., additional, Olszyk, O., additional, Vanhuyse, M., additional, Amela, E., additional, Jasserand, M., additional, Lartigau, E., additional, and Adenis, A., additional

Published
2009
Full Text
View/download PDF

174. Radiothérapie stéréotaxique robotisée par CyberKnife®: aspects techniques et indications

Author

Bondiau, P.-Y., primary, Bénézery, K., additional, Beckendorf, V., additional, Peiffert, D., additional, Gérard, J.-P., additional, Mirabel, X., additional, Noël, A., additional, Marchesi, V., additional, Lacornerie, T., additional, Dubus, F., additional, Sarrazin, T., additional, Herault, J., additional, Marcié, S., additional, Angellier, G., additional, and Lartigau, E., additional

Published
2007
Full Text
View/download PDF

175. Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT+S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)

Author

Crehange, G., primary, Bonnetain, F., additional, Seng, S., additional, N'guyen, T., additional, Mirabel, X., additional, Marchal, C., additional, Verrelle, P., additional, Roullet, B., additional, Maingnon, P., additional, and Bedenne, L., additional

Published
2007
Full Text
View/download PDF

176. Definitive chemo-radiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study

Author

Conroy, T., primary, Yataghene, Y., additional, Etienne, P. L., additional, Michel, P., additional, Senellart, H., additional, Raoul, J. L., additional, Mineur, L., additional, Rives, M., additional, Mirabel, X., additional, and Adenis, A., additional

Published
2007
Full Text
View/download PDF

179. 141

Author

Crehange, G., primary, Bonnetain, F., additional, Seng, S., additional, Nguyen, T., additional, Mirabel, X., additional, Marchal, C., additional, Verrelle, P., additional, Roullet, B., additional, Bedenne, L., additional, and Maingon, P., additional

Published
2006
Full Text
View/download PDF

180. Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial

Author

Michel, P, primary, Adenis, A, additional, Fiore, F Di, additional, Boucher, E, additional, Galais, M P, additional, Dahan, L, additional, Mirabel, X, additional, Hamidou, H, additional, Raoul, J L, additional, Jacob, J H, additional, Hellot, M F, additional, Prod'Homme, S, additional, and Paillot, B, additional

Published
2006
Full Text
View/download PDF

187. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: A French cooperative study

Author

Peiffert, D., primary, Seitz, J.-F., additional, Rougier, P., additional, François, E., additional, Cvitkovic, F., additional, Mirabel, X., additional, Nasca, S., additional, Ducreux, M., additional, Hannoun-Levi, J.M., additional, Lusinchi, A., additional, Debrigode, E., additional, Conroy, T., additional, Pignon, J.P., additional, and Gérard, J.P., additional

Published
1997
Full Text
View/download PDF

190. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature

Author

Cowen, D., primary, Richaud, P., additional, Mornex, F., additional, Bachelot, T., additional, Jung, G.M., additional, Mirabel, X., additional, Marchal, C., additional, Lagrange, J.-L., additional, Rambert, P., additional, Chaplain, G., additional, N'Guyen, T.D., additional, Resbeut, M., additional, and FNCLCC trialists, The, additional

Published
1995
Full Text
View/download PDF

191. Traitements locorégionaux de métastase(s) cérébrale(s) chez des patients atteints d’un mélanome cutané métastatique : recommandations nationales françaises

Author

Lubrano, V., Derrey, S., Truc, G., Mirabel, X., Thariat, J., Cupissol, D., Sassolas, B., Combemale, P., Modiano, P., Bedane, C., Dygai-Cochet, I., Lamant, L., Mourrégot, A., Rougé Bugat, M.-È., Siegrist, S., Tiffet, O., Mazeau-Woynar, V., Verdoni, L., Planchamp, F., and Leccia, M.-T.

Abstract

The management of metastatic cutaneous melanoma is changing, marked by innovative therapies. However, their respective use and place in the therapeutic strategy continue to be debated by healthcare professionals.

Published
2014
Full Text
View/download PDF

192. Curiethérapie du canal anal.

Author

Pommier, P., Mirabel, X., Hannoun-Lévi, J.-M., Malet, C., Gérard, J.-P., and Peiffert, D.

Subjects
*ANAL cancer treatment, *RADIOISOTOPE brachytherapy, *CANCER radiotherapy, *RADIATION doses, *FLUOROURACIL, *MITOMYCIN C
Abstract

Résumé: La curiethérapie de bas débit de dose est un standard thérapeutique en complément d’une chimioradiothérapie concomitante pour les carcinomes épidermoïdes du canal anal localement évolués, sous réserve d’une sélection rigoureuse portant sur l’évaluation initiale de la maladie et la réponse à la radiothérapie externe. Le taux de contrôle local semble être meilleur lorsque le complément (boost) est délivré par curiethérapie qu’avec la radiothérapie externe. Les différentes étapes de la réalisation de la curiethérapie sont détaillées. Le schéma standard comporte une radiothérapie externe pelvienne de 45Gy en 25 fractions et cinq semaines avec potentialisation par deux cures de 5-fluoro-uracile et mitomycine-C, puis une curiethérapie de 15Gy après deux à trois semaines. Le gain apporté par des doses cumulées plus élevées de radiothérapie en termes de probabilité de survie sans colostomie pour les tumeurs plus évoluées n’a pas été formellement démontré. La curiethérapie exclusive pour les cancers in-situ ou les cancers infiltrants de moins de 10mm n’est pas recommandée du fait d’un risque élevé de récidive locale. La curiethérapie de débit de dose pulsé est une alternative à la curiethérapie de bas débit de dose continu (fils d’iridium) sous réserve de respecter le débit de dose recommandé (0,5 à 1Gy/heure). La curiethérapie de haut débit de dose est en cours d’évaluation. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

197. Radiothérapie stéréotaxique hépatique par CyberKnife® : l’expérience lilloise

Author

Dewas, S., Mirabel, X., Kramar, A., Jarraya, H., Lacornerie, T., Dewas-Vautravers, C., Fumagalli, I., and Lartigau, É.

Subjects
*CANCER radiotherapy, *LIVER cancer, *STEREOTAXIC techniques, *METASTASIS, *RETROSPECTIVE studies, *SURVIVAL analysis (Biometry)
Abstract

Abstract: Purpose: The CyberKnife® system is a recent radiation therapy technique that allows treatment of liver lesions with real-time tracking. Because of its high precision, the dose administered to the tumor can be increased. We report Oscar-Lambret Cancer Centre experience in the treatment of primary and secondary liver lesions. Patients and methods: It is a retrospective study analyzing all the patients who have been treated for their liver lesions since July 2007. A hundred and twenty patients have been treated: 42 for hepatocellular carcinoma, 72 for liver metastases and six for cholangiocarcinoma. Gold seeds need to be implanted before the treatment and are used as markers to follow the movement of the lesion due to respiration. On average, the treatment is administered in three to four sessions over 12 days. A total dose of 40 to 45Gy at the 80% isodose is delivered. Local control and overall survival analysis with Log-rank is performed for each type of lesion. Results: Treatment tolerance is good. The most common toxicities are of digestive type, pain and asthenia. Six gastro-duodenal ulcers and two radiation-induced liver disease (RILD) were observed. At a median follow-up of 15 months, the local control rate is respectively of 80.4% and 72.5% at 1 and 2 years. Overall survival is 84.6 and 58.3% at 1 and 2 years. The local control is significantly better for the hepatocellular carcinoma and overall survival is significantly better for liver metastases (P <0.05). The local control rate and overall survival at 1 year for cholangiocarcinoma is 100%. Conclusion: CyberKnife® is a promising technique, well tolerated, with tumoral local control rates comparable to other techniques. Its advantage is that it is very minimally invasive delivered as an outpatient procedure in a frail population of patient (disease, age). [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

199. Le CyberKnife® : expérience du centre Oscar-Lambret

Author

Lacornerie, T., Mirabel, X., and Lartigau, E.

Subjects
*RADIOTHERAPY, *MEDICAL imaging systems, *RESPIRATION, *QUALITY control, *MEDICAL radiology
Abstract

Abstract: In June 2007, the CyberKnife® has been implemented at Centre Oscar-Lambret in Lille. The program has been developed around specific clinical indications: head and neck reirradiation, liver. Early results are presented. The system includes several way of repositioning fixed targets and tracking moving targets with breathing. With each way, there is a dedicated tool for the quality control. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results